Table 3.
Lipids of a Cohort of 553 HIV-Infected and 300 HIV-Uninfected Children Aged 4–9 at Two Study Sites in Johannesburg, South Africa, Stratified by HIV Status
| Lipid, mg/dL |
HIV Infected
(N = 553) |
HIV Uninfected
(N = 300) |
P Value |
|---|---|---|---|
| Total Cholesterol, N (%) | |||
| Acceptable: (<170) | 266 (48.5) | 229 (76.3) | <.0001 |
| Borderline: (170–199) | 163 (29.7) | 56 (18.7) | |
| Elevated: ≥200 | 120 (21.9) | 15 (5.0) | |
| LDL, N (%) | |||
| Acceptable: (<110) | 384 (70.0) | 260 (86.7) | <.0001 |
| Borderline: (110–129) | 90 (16.4) | 28 (9.3) | |
| Elevated: (≥130) | 75 (13.7) | 12 (4.0) | |
| Non-HDL, N (%) | |||
| Acceptable: <120 | 305 (55.6) | 235 (78.3) | <.0001 |
| Borderline: 120–144 | 114 (20.8) | 46 (15.3) | |
| Elevated: ≥145 | 130 (23.7) | 19 (6.3) | |
| HDL, N (%) a | |||
| Abnormal: (<35) | 38 (6.9) | 23 (7.7) | .6878 |
| Normal: (≥35) | 511 (93.1) | 277 (92.3) | |
| HDL, N (%) b | |||
| Low: (<40) | 77 (14.0) | 49 (16.3) | .6611 |
| Borderline (40–45) | 72 (13.1) | 39 (13.0) | |
| Acceptable: (>45) | 400 (72.9) | 212 (70.7) | |
| Triglycerides, N (%) a | |||
| Normal: (≤150) | 429 (78.1) | 276 (92.0) | <.0001 |
| Abnormal: (>150) | 120 (21.9) | 24 (8.0) | |
| Triglycerides, N (%) b | |||
| Acceptable: (<75) | 132 (24.0) | 164 (54.7) | <.0001 |
| Borderline: (75–99) | 115 (21.0) | 70 (23.3) | |
| Elevated: (≥100) | 302 (55.0) | 66 (22.0) | |
| Number of Dyslipidemiasb | |||
| 0 | 187 (34.1) | 196 (65.3) | <.0001 |
| 1 | 202 (36.8) | 69 (23.0) | |
| 2 | 111 (20.2) | 33 (11.0) | |
| ≥3 | 49 (8.9) | 2 (0.7) | |
Abbreviations: HDL, high-density lipoprotein; HIV, human immunodeficiency virus; LDL, low-density lipoprotein.
aCategories based on National Cholesterol Education Program Expert Panel on Cholesterol Levels in Children [42, 43].
bCategories based on Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents [44].